Theratechnologies (THTX) Peer Comparison
$3.39
$0.00 (0.00%)As on 02-Oct-2025 09:30EDT
Market cap
$156 Mln
Revenue (TTM)
$84 Mln
P/E Ratio
--
P/B Ratio
20.1
Div. Yield
0 %
Edit
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
156 | 2,409 | 1,219 | 1,031 | 22 |
Revenue ($ Mln) |
84 | 10,853 | 243 | 182 | -- |
Net Profit ($ Mln) |
-9.16 | -1,098.00 | 69.79 | 153.05 | -24.89 |
Net Margin (%) |
-10.85 | -10.12 | 28.74 | 84.23 | -- |
RoE (%) |
-- | -- | 5.60 | 91.29 | -331.14 |
Price to Earnings |
-- | -- | 17.42 | 6.06 | -- |
Price-To-Book |
20.13 | 18.78 | 1.14 | 3.64 | -- |
Cashflow ($ Mln)
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2.38 | 1,597.00 | 18.84 | -64.85 | -6.88 |
|
Cash Flow from Investing Activities
|
0.94 | -454.00 | 175.15 | 22.95 | -1.50 |
|
Cash from Financing Activities
|
-21.49 | -868.00 | -1.23 | 52.00 | 11.62 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-28.43 | -0.22 | 3.79 | -64.08 | -109.75 |
|
ROE (%)
|
36.00 | 4.00 | 3.80 | -68.76 | -114.92 |
|
ROA (%)
|
-12.67 | -0.17 | 3.56 | -50.65 | -82.11 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-9.67 | -0.48 | 34.93 | -1,133.04 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.05 | 0.10 | 0.35 | -0.66 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
65.33 | 92.23 | 155.54 | 4.02 | 20.66 |
|
EPS Growth (%)
|
-- | 0.92 | 1.55 | 0.15 | 0.53 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -65.18 | 19.01 | -8.88 | -0.27 |
|
Price / Book Value
|
-- | -2.34 | 0.73 | 6.38 | 0.33 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
5.23 | 7.54 | 1.51 | -7.38 | 0.18 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.80 | -17.06 | 0.00 | 0.06 | 0.07 |
|
Short term debt to equity ratio
|
-0.15 | -2.14 | 0.00 | 0.00 | 0.07 |
|
Current Ratio
|
1.19 | 0.86 | 18.84 | 8.15 | 1.80 |
|
Quick Ratio
|
1.05 | 0.62 | 18.17 | 5.95 | 1.79 |
|
Interest Coverage
|
0.40 | 1.35 | -- | -509.36 | -312.50 |
Operating Efficiency Ratios
| Theratechnologies (THTX) | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Quantum BioPharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.17 | 22.23 | 25.31 | 39.04 | -- |
|
Asset Turnover
|
1.31 | 0.36 | 0.10 | 0.04 | 0.00 |
|
Receivable days
|
62.01 | 78.51 | 101.93 | 123.85 | -- |
|
Inventory Days
|
101.34 | 206.06 | 125.77 | -470.06 | 43.65 |
|
Payable days
|
118.93 | 90.26 | 57.51 | 733.01 | 2,418.08 |
|
Cash Conversion Cycle
|
44.42 | 194.31 | 170.19 | -1,079.22 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
